WO2023129050 - A PHARMACEUTICAL COMPOSITION OF EMPAGLIFLOZIN AND LINAGLIPTIN PROCESSED WITH HOT-MELT EXTRUSION
National phase entry:
Publication Number
WO/2023/129050
Publication Date
06.07.2023
International Application No.
PCT/TR2022/051598
International Filing Date
26.12.2022
Title **
[English]
A PHARMACEUTICAL COMPOSITION OF EMPAGLIFLOZIN AND LINAGLIPTIN PROCESSED WITH HOT-MELT EXTRUSION
[French]
COMPOSITION PHARMACEUTIQUE D'EMPAGLIFLOZINE ET DE LINAGLIPTINE TRAITÉE PAR EXTRUSION À CHAUD
Applicants **
SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI
Inventors
YANC, Burcin
ULUSOY BOZYEL, Muge
SUNEL, Fatih
Priority Data
2021/021295
28.12.2021
TR
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
Turkpatent
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1964 | |
| EPO | Filing, Examination, Granting | 9311 | |
| Japan | Filing, Examination, Granting | 2055 | |
| South Korea | Filing, Examination, Granting | 1829 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
19,899
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to a pharmaceutical composition comprises a granulate comprising empagliflozin or salts thereof and linagliptin or salts or crystalline polymorph thereof, wherein the granulate is obtained by hot melt extrusion.[French]
La présente invention concerne une composition pharmaceutique comprenant un granulé comprenant de l'empagliflozine ou des sels de celle-ci et de la linagliptine ou des sels ou un polymorphe cristallin de celle-ci, le granulé étant obtenu par extrusion à chaud.